GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Total Inventories

HLS Therapeutics (HLS Therapeutics) Total Inventories : $9.53 Mil (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Total Inventories?

HLS Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $9.53 Mil. HLS Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $9.14 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. HLS Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-2.42.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. HLS Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 329.39.

Inventory Turnover measures how fast the company turns over its inventory within a year. HLS Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.28.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. HLS Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.58.


HLS Therapeutics Total Inventories Historical Data

The historical data trend for HLS Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Total Inventories Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.06 10.63 8.93 8.90 9.53

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.90 10.71 9.97 8.75 9.53

HLS Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


HLS Therapeutics  (OTCPK:HLTRF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

HLS Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(21.952+0.75 * 9.64+0.5 * 9.534-111.363
-0-0)/31.9799
=-2.42

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

HLS Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=9.1435/2.533*365 / 4
=329.39

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

HLS Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=2.533 / 9.1435
=0.28

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

HLS Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=9.1435 / 15.863
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


HLS Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (HLS Therapeutics) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA 03-21-2013